MSKCC

New York, New York 10065

3 studies enrolling now · 16 studies all time

What they study most

Acute Graft vs Host Disease, Advanced Angiosarcoma, Advanced Malignant Neoplasm, Amyloidosis, DLBCL, Follicular Lymphoma, Gastrointestinal Stromal Tumors, Giant Cell Tumor of Tendon Sheath, Graft Versus Host Disease (GVHD), Hematologic Malignancy, Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin

Studies at this site

• A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma — Recruiting now
• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma — Running, not enrolling
• Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone — Completed
• Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor — Running, not enrolling
• IS-002 Phase 2 Prostate Cancer Study — Completed
• A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies — Enrolling by invitation
• Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies — Stopped early
• Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer — Completed
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — Stopped early
• A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma — Stopped early
• Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy — Stopped early
• Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies — Completed
• Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD — Completed
• Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma — Completed
• Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis — Completed